Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and
methotrexate, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving sunitinib together with combination
chemotherapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib when
given together with cyclophosphamide and methotrexate to see how well they work in treating
patients with metastatic breast cancer.